TG Therapeutics (TGTX) Continuing to Drive on All Cylinders; Roth Affirms 'Focus Pick' Rating
Roth Capital reaffirms TG Therapeutics, Inc. (Nasdaq: TGTX) with a Focus Pick rating and $33 price target following Q2 results ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)